Tokyo Tape
Sign in
← Kaken Pharmaceutical

Half-year report · Q2

4521.TEDINET S100UP1J
Period2024-04-01 → 2024-09-30
Filed2024-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥51.4bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥72.0bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥36.2bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥19.6bn2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥5.5bn2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥19.8bn2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥10.0bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥5.7bn2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥19.2bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥5.7bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)¥14.3bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥8.0bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥4.1bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income¥14.3bn2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥4.1bn2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥187.1bnat 2024-09-30Cons.Assets
Total assets¥171.6bnat 2024-03-31Cons.Assets
Total assets¥171.7bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥32.7bnat 2024-09-30Cons.Liabilities
Total liabilities¥27.9bnat 2024-03-31Cons.Liabilities
Net assets / equity¥154.4bnat 2024-09-30Cons.Net assets
Net assets / equity¥143.8bnat 2024-03-31Cons.Net assets
Net assets / equity¥140.7bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥67.3bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥50.6bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥84.0bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥65.3bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥70.1bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥74.3bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥23.9bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥2.6bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥245m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥2.4bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥5.9bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.1bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥2.8bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥5.7bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥2.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥377.232024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥212.672023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥108.182023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio82.5%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio83.8%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio82.0%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 18
SegmentItemPeriodValue
jpcrp040300-q2r_E00935-000Medicinereportable segmentrevenue2024-04-01 → 2024-09-30¥50.1bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentrevenue external2024-04-01 → 2024-09-30¥50.1bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentsegment profit2024-04-01 → 2024-09-30¥18.9bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentrevenue2024-04-01 → 2024-09-30¥1.2bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentrevenue external2024-04-01 → 2024-09-30¥1.2bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentsegment profit2024-04-01 → 2024-09-30¥676m
Total Of Reportable Segments And Otherssegment totalrevenue2024-04-01 → 2024-09-30¥51.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-04-01 → 2024-09-30¥51.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2024-04-01 → 2024-09-30¥19.6bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentrevenue2023-04-01 → 2023-09-30¥35.0bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentrevenue external2023-04-01 → 2023-09-30¥35.0bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentsegment profit2023-04-01 → 2023-09-30¥4.9bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentrevenue2023-04-01 → 2023-09-30¥1.2bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentrevenue external2023-04-01 → 2023-09-30¥1.2bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentsegment profit2023-04-01 → 2023-09-30¥661m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥36.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥36.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥5.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 490
ItemContextValueUnit
Noncurrent liabilitiesPrior1YearInstant8843000000JPY
Noncurrent liabilitiesCurrentQuarterInstant9034000000JPY
LiabilitiesPrior1YearInstant27868000000JPY
LiabilitiesCurrentQuarterInstant32718000000JPY
Capital stockPrior1YearInstant23853000000JPY
Capital stockCurrentQuarterInstant23853000000JPY
Capital surplusPrior1YearInstant11462000000JPY
Capital surplusCurrentQuarterInstant11500000000JPY
Retained earningsPrior1YearInstant128506000000JPY
Retained earningsCurrentQuarterInstant139949000000JPY
Treasury stockPrior1YearInstant-28613000000JPY
Treasury stockCurrentQuarterInstant-28629000000JPY
Shareholders equityPrior1YearInstant135207000000JPY
Shareholders equityCurrentQuarterInstant146674000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant7184000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant6408000000JPY
Remeasurements of defined benefit plansPrior1YearInstant1363000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant1322000000JPY
Valuation and translation adjustmentsPrior1YearInstant8547000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant7731000000JPY
Net assetsPrior1YearInstant143755000000JPY
Net assetsCurrentQuarterInstant154405000000JPY
Liabilities and net assetsPrior1YearInstant171623000000JPY
Liabilities and net assetsCurrentQuarterInstant187123000000JPY
Net salesPrior1YTDDuration36171000000JPY
Net salesCurrentYTDDuration51372000000JPY
Cost of salesPrior1YTDDuration16450000000JPY
Cost of salesCurrentYTDDuration17269000000JPY
Gross profitPrior1YTDDuration19720000000JPY
Gross profitCurrentYTDDuration34103000000JPY
Salaries sgaPrior1YTDDuration2821000000JPY
Salaries sgaCurrentYTDDuration2804000000JPY
Bonuses and provision for bonuses sgaPrior1YTDDuration553000000JPY
Bonuses and provision for bonuses sgaCurrentYTDDuration539000000JPY
Retirement benefit expenses sgaPrior1YTDDuration136000000JPY
Retirement benefit expenses sgaCurrentYTDDuration82000000JPY
Research and development expenses sgaPrior1YTDDuration5738000000JPY
Research and development expenses sgaCurrentYTDDuration5973000000JPY
Other sgaPrior1YTDDuration4957000000JPY
Other sgaCurrentYTDDuration5123000000JPY
Selling general and administrative expensesPrior1YTDDuration14207000000JPY
Selling general and administrative expensesCurrentYTDDuration14523000000JPY
Operating incomePrior1YTDDuration5512000000JPY
Operating incomeCurrentYTDDuration19579000000JPY
Interest income noiPrior1YTDDuration4000000JPY
Interest income noiCurrentYTDDuration15000000JPY
Dividends income noiPrior1YTDDuration251000000JPY
Dividends income noiCurrentYTDDuration288000000JPY
Other noiPrior1YTDDuration22000000JPY
Other noiCurrentYTDDuration37000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass
balance sheet identityconsolidated 2024-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass